Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of E6011 in Rheumatoid Arthritis Patients Inadequately Responding to Biologics
jRCT2080223392Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing E6011 400 mg then 200/400 mg plus methotrexate with Placebo then switch to E6011 plus methotrexate (2 arms). Primary endpoint: ACR20 response rate at Week 12. Started Nov 2016; status: completed.
02
Drugs
quetmolimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080223392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223392.